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Abstract:
Wounds care and management is one of the most basic needs in the medical setting. Burn
wounds, trauma wounds, pressure ulcers and bedsores are just some of the many types of
wounds that need to be treated quickly and efficiently. Take for instance pressure ulcers, there at
least 3 million reported cases of chronic ulcers and bedsores reported in the U.S. each year alone.
Each ulcer can takes weeks to months to fully heal, leading to extended hospital stays and
decreased quality of life in patients. Current treatment seeks to protect and keep the wound clean,
manage cellular exudates, and in general reduce wound area. This is done by packing antibiotic
gels into the wound bed, which have a bolus drug release profile, and covering the area with
commercially available bandages. There are many studies documenting bolus drug release
profiles and their effects on wounds, but what is distinctly absent are studies which investigate
the effects of continuous drug delivery on wound healing.

Here it is hypothesized that applying a continuous flow of fresh drugs into the wound bed
will speed up the often lengthy wound healing process. To examine this hypothesis, human
umbilical vein endothelial cells (HUVEC) and adult human dermal fibroblasts (HDFa) cell
culture models were used to mimic the wound healing process. Results were characterized by the
rate of cell migration and proliferation (wound closure) into a simulated wound channel created
in the middle of nearly confluent HUVEC and HDFa cell culture models. Both cell types were
exposed to static or continuous flow conditions with and without drug infused media. For the
HUVEC cells testing indicates a significant difference between the average rate of closure for
flow versus no flow conditions (0.0628 versus 0.0232 percent closure per minute, p = 0.00165).
For the HDFa cells testing indicates a significant difference between the average rate of closure
4

for flow versus no flow conditions (0.0595 versus 0.0392 percent closure per minute, p =
0.01606). The research suggests that positive growth rate occurs in HDF and HUVEC when
continuous low flow conditions are applied to the cells.
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Introduction:
Wound Healing Process of Chronic Wounds:
Over 3 million Americans are afflicted with pressure ulcers, bedsores, and other related
wounds each year. They are classified on a scale from 1 to 4, where 1 is redness of skin with
some pain on contact and 4 is full thickness tissue loss down to the bone [1, 2]. The healing
process for these types of wounds can often take weeks, and can be very labor intensive for staff
to treat. The wound healing process in general is composed of five steps hemostasis,
inflammation, migration, proliferation, and remodeling. The hemostasis phase occurs
immediately after the initial wound and is indicated by the clotting cascade causing the bleeding
to stop [3]. Fibrinogen elicits the clotting mechanism and in conjunction with the establishment
of the fibrin network, resulting in the formation of the clot [4]. The inflammatory phase occurs
nearly simultaneously with the hemostasis phase and primarily includes the congregation of
neutrophils at the site of the wound. Also present during this phase is the vasodilation of
surrounding vessels in an attempt to get blood to the site of the wound. The migration and
proliferation phases are of the most interest to the wound healing process because they are the
most easily altered to speed up the wound healing process [3].

The migration phase is characterized by the movement of epithelial cells and fibroblasts
to the wound bed in an attempt to replace damaged or destroyed tissue. Proliferation is initiated
by the further filling of the wound bed by growing and dividing new cells. Granulation tissue is
formed as blood and lymph vessels are reestablished. This phase is also characterized by
thickening of the epithelial layer [5]. These two phases can take anywhere from a few days to
weeks to complete, which is why shortening these two phases is very important in managing the
7

wound healing process. The final phase is the remodeling phase where connective tissue is
formed to strengthen the new epithelium. This final phase can take anywhere from a month to a
year to complete depending on the effectiveness of the administered treatments early on [3].

Current Techniques to Treat Chronic Wounds:
The techniques used to treat chronic wounds all seek to accomplish a few things. These
goals are to manage exudates [6], debridement of the wound [7], protecting the wound from
infection, and be low maintenance [8, 9]. Clinically there are a few methods used to treat chronic
ulcers or bedsores, most include a combination of wound dressings and topical gels. The wound
is typically cleaned with an isotonic saline solution to remove foreign contaminants. Depending
on the type of wound a variety of pharmaceutical therapies can be administered. These include
silver nitrate [10], a silver sulpha-diazine [11, 12], antibiotics, antimycotics [3], or drugs that
promote angiogenesis and granular tissue growth (e.g., RegranexTM) [13]. These different
treatment modalities require several treatments/day, which can lead to variations in the amount
of therapeutic used [14, 15]. Another mechanism of treatment used for extreme cases is a tissue
graft transplant to fill in the affected area [16, 17]. Apligraf is one such example of a skin
substitute which contains living cells and structural proteins to act as a scaffold for new tissue
regeneration. One thing all these methods have in common is that when a drug is applied, it has a
bolus release profile that in no way maintains a constant concentration of the drug being
delivered to the wound [3, 18]. A more recent method of treatment for wounds is vacuum or
negative pressure therapy. Vacuum therapy works by pulling exudates out of the wound rather
than allowing them to merely seep out of the wound resulting in a faster mechanism of action.
The vacuum therapy also results in a mechanical tension on the underlying tissue which results
8

in dilated arterioles and an increased blood supply to the wound [19, 20]. Vacuum therapy
treatment is the closest to being called a continuous flow treatment that is currently available.
The fact that so much research is being thrust into vacuum therapy lends credence to the idea that
continuous flow will greatly benefit wounds and should be explored.

Continuous Drug Delivery with Novel Knudsen Pump
Currently being developed is a pump which is capable of providing continuous
circulation of fluids without power, using only thermal gradients. Since it doesn’t need a power
supply, it is able to be made small and would be perfectly suited for wound healing especially
when incorporated into a bandage or other wound dressing. Theoretically, this pump is able to
produce flow rate between 0.01 and 0.25 mL/min in a constant fashion based on the thermal
gradient generated between the skin and the ambient air temperature. The development of this
device and the introduction of it into the field of medical devices poses new questions about the
effects of flow on wound healing. Very little research has been conducted into low flow effects
on healing wounds as well as continuous perfusion of a drug into the wound. The creation of this
novel device is partially what prompted this investigation. The flow parameters used in testing
were restricted to those flow rates capable of being generated by the device.

Known Flow Effects on Cells:
Some recent experimentation has been conducted to look at the effects of shear stress on
simulated wound HUVEC cell culture models [21]. One such experiment presheared the cells for
18 hours at 12 dyn/cm2 to obtain alignment of the cells in the direction of the flow field. After
which they sheared the cells at values of 3, 12, and 20 dyn/cm2. Results of testing showed
increased wound closure at all levels of shear stress over the static conditions. In addition they
9

found that the lower shear stress value 3 dyn/cm2 produced a significant effect on wound healing
over the higher shear stress values [22, 23]. It is important to note that these levels of shear stress
are radically higher than those capable of being produced by the continuous flow pump described
above. Another such investigation examined at what levels of shear HUVEC cells began to
display different cellular adhesion molecules. They found that at shear levels around 8 dyn/cm2
there is a significant upregulation of ICAM-1 and E-selectin, two cellular adhesion molecules
[24, 25, 26]. At shear stress levels lower than 8 dyn/cm2, these effects were not significantly
altered. This information provides a shear stress threshold at which the HUVEC cells can be
expected to begin differentiation. There is little to no data regarding flow effects with shear stress
lower than 3 dyn/cm2 on HUVEC cells and there is no data investigating this effect on HDFa
cells. It would be beneficial to explore the relationship between shear stress lower than 3
dyn/cm2 and the resulting cellular growth rates.

Known Effects of VitaSol on Cells:
The effect of VitaSol, an ATP lipid vesicle formulation, on cells has been extensively
reported in the literature. In one example, VitaSol was tested in a nude mouse wound healing
model. A small incision was made on the head and covered with a protective bandage soaked
with the ATP lipid vesicles. When compared to the control treatment it was shown that that
VitaSol significantly reduced wound area and healed the wound faster. The VitaSol also had a
marked positive effect on the reepithelialization and granular tissue shown in histological studies
as well as a significant increase in a produced revascularization growth factor, VEGF [27, 28].
Another study used VitaSol in an attempt to speed the wound closure rates in an ischemic rabbit
ear model. For this investigation the VitaSol was again applied as a drug soaked bandage. The
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results of this experimentation concluded similar results to the first, in terms of wound closure
rates the VitaSol significantly reduced to number of days until full healing when compared to a
saline control [29, 30]. It is important to note the delivery mechanism of the VitaSol treatment.
For each conducted investigation the delivery method was a bolus profile. A drug soaked
bandage was applied to the wound and was changed daily. This means a higher concentration of
the drug will be released initially which will eventually tapper off. It is unknown how the drug
will behave when applied to a wound at a constant concentration through continuous flow. It is
expected that the displayed effects would be even greater than those demonstrated by these
articles. These are just two examples of studies conducted using ATP infused lipid vesicles and
the effects they are capable of. Intracellular absorption of ATP has also been shown to upregulate
certain growth factors suspected to assist in the wound healing process [31].

Purpose of Research:
The goal of this research investigation is to characterize the effect of flow conditions on
several types of cell culture models and assess the potential it has to overcome the previously
mentioned drawbacks to current wound therapies. Some research has been done to study the
effects of flow on HUVEC cell culture models as it pertains to wound healing rates, however, all
research that has been conducted dealt with extremely high flow rates and shear stresses, well
outside the realm of what the continuous flow device being developed is capable of. Currently
published research also does not investigate what effects, if any, flow has on HDFa cells. In the
field of research there is a need to characterize the effects of low flow on HUVEC and HDFa
cells as it applies to the wound healing process, which is what this investigation seeks to
accomplish.
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Discussion of Model Used:
For this investigation HUVEC and HDFa cells were chosen to model the behavior of a
healing wound. During the wound healing process it is known that fibroblasts play a key role in
filling the wound bed. This filling of the wound plays a crucial role in the overall recovery time
as it protects the wound from infections which, if the wound becomes septic slows the wound
healing substantially. Another crucial aspect of the wound healing process is the
revascularization and angiogenesis of new blood vessels in to wound area to replace the vessels
that were destroyed or damaged at the time of the initial wound creation. Reestablishing blood
flow and a fresh nutrient supply to the wound bed ensures that cells have all the supplements
they need for optimal growth rates. Reforming this complex network of blood vessels faster
should in turn allow the rest of the cells to close the wound faster. It is widely accepted that
HUVEC cells are a suitable cell line to model revascularization which is why they too were
chosen for this investigation.

Hypotheses:
It is hypothesized that an application of continuous flowing media over the cells will
increase the observed growth rate of HUVEC and HDFa cells over no flow media conditions. It
is further hypothesized that the flow of media will increase metabolic rates and mitochondrial
activity in HUVEC and HDFa culture models. Finally, it is hypothesized that adding ATP
infused lipid vesicles will substantially increase not only the observed growth rates of the cell
cultures but also have a marked effect on the mitochondrial activity obtained through the MTT
assay.
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Instrumentation:
This section contains specific information regarding the instrumentation used throughout
the duration of this experimentation.
Fluorescence Spectrometer:
Fluorescent readings were taken using a LS 50B Fluorescence Spectrometer (Perkin
Elmer, Waltham, MA) using a cuvette with optical path length of 10 mm. Slits for excitation and
emission beam were set to 15 and 20, respectively.
Dynamic Light Scattering Detector:
DLS measurements used to measure vesicles radius were taken using a Protein Solutions
DynaPro Titan with Temperature Controlled MicroSampler (Wyatt Technology, Santa Barbara,
CA) using a cuvette with 10 mm optical path length. Scans were performed at temperatures 37°C
with a scattering angle of 90o. DI water was used as a standard.
Spectrophotometer:
Absorption scans to measure protein and MTT assays were taken using GENESYS 10S
UV-Vis spectrophotometer (Thermo Scientific, Pittsburgh, PA) using a cuvette with 10 mm
optical path length. Scans were performed at the correct wavelength depending on the
experiment.
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Procedure:
Before conducting the primary wound closure rate experiment, smaller verification
experiments had to be conducted to ensure the proper criteria were met for the main design. Each
of these verification steps is detailed in the subsections below with a description of the materials
required to complete the task.

Making the VitaSol:
For the purposes of this experimentation, two of the testing groups will be given a dosage
of ATP such that the cells experience a 0.1 mg/mL working concentration of the drug with a 5
mmol ATP concentration in HBSS. To make the drug according to these specifications the
following steps were conducted. To make VitaSol: mix soy phosphatidylcholine 95% (SOYPC,
Avanti Polar Lipids, Alabaster, Alabama) in solid form and 1, 2-dioleyol-3-trimethylammonium-propane (DOTAP, Avanti Polar Lipids, Alabaster, Alabama) dissolved in chloroform
in a weight ratio of 50:1 respectively.

The lipids were weighed out and mixed together in a 50 mL plastic test tube. Once mixed
it is necessary to dry off the chloroform from the mixture. To do this nitrogen gas is blown over
the lipids while gently rotating the test tube to speed up the drying process. Once the lipids
appear dry the test tube is placed into a vacuum chamber overnight to further remove any traces
of chloroform.
The next day the lipids were rehydrated using a stock solution composed of DI water,
ATP magnesium salt (5 mM, Avanti Polar Lipids, Alabaster, Alabama), Trizma Base (25 mM,
Sigma-Aldrich, St. Louis, Missouri), and hanks balance salt solution (HBSS) (9.5 g/L, Sigma14

Aldrich, St. Louis, Missouri). To make the stock solution the three solid components were
weighed out in the proper quantities, added to the correct volume of DI water, and mixed
thoroughly.
Once the stock solution had been created it was added to the lipids along with several
glass beads. The resulting solution was then vortexed to fully rehydrate the lipids in the stock
solution. This rehydration process may take anywhere from 20 minutes for small batches to 2
hours for larger batches of VitaSol. It is important to try to keep the solution at room temperature
and covered with aluminum foil to limit any light interactions that may occur which can degrade
the lipid vesicles.
After rehydration it was necessary to sonicate the sample to reduce aggregation of the
lipid vesicles and bring down the average hydrodynamic radius of the particle. Samples were
sonicated for 10 minutes at a 50% duty cycle (Branson Sonifer, VWR Scientific, Radnor,
Pennsylvania). The VitaSol solution was then centrifuged for 10 minutes at 2000g to remove any
titanium contaminants that flaked off from the sonicator probe.
After centrifugation the VitaSol was extruded through a 0.1 μm filter using a nitrogen
cavitation bomb (Parr Instruments, Moline, Illinois). This further refines the average size of the.
The extrusion process is completed by pressuring a reservoir containing the VitaSol to around
300 to 600 psi at 40oC using a water jacket or circulating water bath. After the extrusion the
resulting VitaSol solution was ready for use in experimentation, although the size and pH were
verified first.
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The pH was checked to be around 7.4 since this is physiologic conditions. The pH was
tested by using a calibrated pH probe (Oakton pH Tutor, Cole-Parmer, Vernon Hills, Illinois)
immersed in the VitaSol solution. To measure the hydrodynamic radius of the lipid vesicles of
VitaSol, a 50 μL sample was placed in a 450 μL of sample buffer and equilibrated to room
temperature. The VitaSol solution was measured using a Protein Solutions Dyna Pro Dynamic
Light Scattering device. Roughly 60 to 100 unique measurements, taken at a count rate of 5000
per measurement, were taken from the sample to ensure that the size was around 100-120nm in
radius with a fairly low poly dispersity index. The sample is considered usable as long as the
average size is kept less than 150 nm in radius. This is how all VitaSol testing solutions were
created for the duration of these experiments.

Vesicle Binding By Native Media Proteins:
It is known that the proteins in the culture media can have a binding affinity for certain
substances introduced into the media. In terms of this experimentation the ratio of injected ATP
lipid vesicles bound by the native media proteins was unknown and needed to be quantified so
the proper dosage of VitaSol could be given to the cells. This binding ratio was determined
through a column separation technique.

The lipid vesicles were labeled with Nile red (Molecular Probes-Invitrogen, Eugene,
Oregon) dissolved in a solution of 25% dimethyl sulfoxide (DMSO) 75% deionized water, such
that a final working concentration of 1 mg/mL was achieved [32, 33]. The Nile red stock solution
was then added to the VitaSol solution in a ratio of 1:50 respectively and allowed to sit in a 4oC
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environment for 1 hour. This resulted in Nile red dye becoming trapped in the lipid bilayer due to
hydrophobic interactions between the Nile red molecule and the inner bilayer space.

The labeled vesicle solution was added to the culture media in a 1:1 ratio. Since two cell
culture types are going to be used, each required a binding profile to be established. The media
being tested is the EGM-2 media (Lonza-Clonetics, Basel, Switzerland) for the HUVEC cells
and M-106 media (Gibco-Cascade Biologics, Eugene, Oregon) for the HDFa cells. Once
combined the testing sample was placed in the incubator at 37oC and left to sit overnight (at least
12 hours). In order to separate the unbound lipids from the media proteins, a Sepharose-2B
(Sigma-Aldrich, St. Louis, Missouri) packing agent was used in a column length of 40 cm [34].
When pouring the column the Sepharose gel was diluted in a small amount of the running buffer
in a ratio of 4:1 respectively [35]. A depiction of the setup is shown in Appendix I Photo 1. In
order to test the media samples, 1 mL of the lipid vesicle/media combination was taken and
loaded into the gel column. As the sample began to flush through the column, collection samples
were collected in 1 mL intervals for further analysis. Collection of the samples was stopped 5
mL after the media band was no longer visible which made sure the entire sample had been
collected. Throughout the duration of the experiment roughly 25 mL of samples was collected
for the EGM-2 media and 30 mL of samples was collected for the M-106 media. It was decided
that an N=3 would be required to generate an accurate assessment of the ratio of bound lipid
vesicles, so for each media type three unique media sample were run.

Once these samples were collected it was necessary to run both a fluorescence
measurement and a BCA assay measurement on them. Fluorescence measurements were
17

obtained using a luminescent spectrometer (Perkin-Elmer, Model# LS50B) and reading the
fluorescence measurement at an excitation wavelength of 533 nm and an emission wavelength of
544 nm. The BCA assay was conducted using the test tube method. The test tube method
required 0.1 mL of each unknown sample to be pipetted into individual glass test tubes. 2 mL of
the working reagent was then added to each sample. The working reagent was created by mixing
together in a 50:1 ratio reagent A to reagent B respectively. Once the working reagent had been
added to the test sample, each of the glass test tubes were covered and placed in the incubator at
37oC for 30 minutes. Each sample, after incubation, was read by a spectrophotometer (ThermoScientific, Model# Genesys 10-S) at a wavelength of 562 nm.

With this information known one can now estimate the sum of the area under the lipid
fluorescence curve and compare that to the sum of the area under the protein bound lipid curves.
Since the exact equation of the curve is unknown a trapezoidal approximation was conducted to
get as close to the actual area as possible. The trapezoidal approximation for each of the media
samples can be found in Appendix II Chart 1 for the EGM-2 media and Chart 2 for the M-106
media. Looking at the results it is clear that in both media conditions a little over half of the
injected lipid vesicles are bound by the native proteins, meaning that for the desired 0.1 mg/mL
working concentration to be attained 0.2 mg/mL must be injected into the culture media. This
number the guidance for how much of the lipid vesicle mixture should be added to the media in
future experiments in order to achieve the correct working concentration.
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Flow Field Verification:
Since the primary observation of these experiments is the rate change as it pertains to
flow, needless to say the flow characteristics the cells are experiencing are quite important. Flow
rate, shear stress, and type of flow all needed to be defined and were determined via dye
injection analysis [36]. For this verification dye was injected into the DI water being pumped
through the system. The trajectory of the dye particles was observed under the microscope and
caught on the camera system by taking video. The video was then analyzed in slow motion to
obtain the flow velocity of the particles moving through the system. Knowing the velocity the
shear stress could then be calculated as well as the Reynolds number to determine the type of
flow. Also in the video the particles were tracked to see if any types of vortexing or swirling
were present which would tend to indicate a more turbulent flow. Example photographs of how
this verification were conducted are shown below in Appendix I Photo 6-8

Wound Closure Rate Experiments:
HUVEC and HDFa Culture and Passage
For this experimentation all cellular samples needed to complete the testing sets were cultured
prior to testing and frozen back in cryopreservation. To do this 1o HUVEC and 1o HDFa cells
(Lonza, Walkersville, Maryland) were clonally expanded to achieve the desired passage number
(4 o). Once the cells reached the desired passage number they were divided out into individual
vials containing the exact number of cells required to plate the specialized RC-40 glass bottom
dishes (Wilco Wells, Amsterdam, Netherlands) used with the DH-40i microincubation system
(Warner Instruments, Hamden, Connecticut) used during testing. A depiction of the incubation
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system can be found in Appendix I Photo 2. Each dish should be optimally plated with 50,000
cells so this was the number chosen to cryopreserve the cells at. This meant that all testing
samples were kept at the exact same passage number, and from the same cultured cell line.

Setting Up the Microincubation System:
The microincubation system was specifically designed to culture cells under continuous
view from a microscope. For this reason thermal controls and heating elements as well as media
pumping lines all had to be condensed to fit on a standard microscope stage. The DH-40i system
has flow ports built in so it was easy enough to connect sterile tubing lines to the incubation
system, run them through a dual peristaltic pump, one capable of both pumping in fluid and
pulling it back out, and finally connect the tubing to a sterile media reservoir. The heating
elements are also built into the incubation system and are designed to be able to maintain the
ideal temperature of 37oC needed to culture the cells. This ability to maintain the temperature of
the system was verified using a handheld IR thermometer as well as a thermocouple. This
verification step is displayed in Appendix I Photo 3. Prior to each experiment the tubing
transporting the media as well as the cover dish on the microincubation system were autoclaved
to cut down on the risk of infection. A photo of the final setup can be found in Appendix I Photo
4.

Preparing and Testing Samples:
Once the culturing system was functional, testing could begin, however, since the culture
dishes were all glass bottom dishes it was necessary to gelatinize the dishes prior to plating the
cells in order to initiate adhesion sites. This was done by allowing the glass bottom dishes to
20

incubate overnight with a 0.1 % gelatin coating. The 0.1 % gelatin solution was created by taking
0.1 g of the gelatin powder (Sigma Aldrich, St. Louis, MO) and adding that to 100 mL of DI
water. The solution was then sterile filtered under the laminar flow hood, aliquoted into sterile
test tubes, and stored in the 4oC refrigerator throughout the duration of experimentation until it
was needed for each sample. Each culture dish was prepped with this gelatin solution before
being plated with either the HUVEC of HDFa cells.

Once plated the cells were allowed to become nearly confluent at which time a 1ml
sterile pipette tip was used to scratch a simulated wound channel directly in the middle of the
wound culture dish. The resultant wound channel should be roughly 1.5 mm to 2 mm in width
with clearly defined borders. Once the channel had been created, the culture dish was placed
inside the microincubation system in a sterile environment under the laminar flow hood, after
which the chamber was sealed to preserve the sterile environment. Once sealed, the setup was
taken to the microscope and connected to both the peristaltic pump and the DC power supply. To
maintain physiologic pH, a 5 mM concentration of HEPES was added to the culture media for
each sample. Once fully connected, initial measurements of the wound channel were taken and
subsequent photos were taken every 15 minutes to track the closure of the wound. Samples were
allowed to run for approximately 15 hours, giving plenty of data to track wound closure rates
over time. After each sample had been tested the culture dish was removed, sterilized, and
disposed of. In addition the microincubation system was cleaned and prepared for the next test
run, at which time the process repeats itself.
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Roughly five samples needed to be run in each of the four testing groups in order to
determine significance. The static flow testing group with regular media and the static flow
testing group with VitaSol doped media were batch processed to speed up the data collection
rate. This means that all five of the samples were run at the same time while taking photos at
discrete measurements manually. The samples in the flow testing group with regular media and
the flow testing group with VitaSol doped media were tested individually using the camera
system and the microincubation stage described above. It is important to note that five samples in
each of the testing groups were run for both the HUVEC and the fibroblast cell culture models.
This is how samples were run to obtain the rate of wound closure measurements.

Data was obtained through a Nikon D90 camera mounted to the microscope imaging the
cells at 10x magnification. This way the cells could be monitored and their growth progress
tracked over time. As mentioned earlier the static flow cells were batch processed, meaning that
six samples were grown and imaged at the same time. The cell chambers were each marked so
that the same location in the wound bed could be imaged each and every time ensuring that the
data is accurate. For the static flow conditions, images were taken every 6-8 hours excluding
overnight. During imaging, two unique locations in each cell culturing dish were photographed,
which made sure that an average wound distance could be obtained for each sample. For the flow
conditions, each sample had to run individually since it had to be placed in the special remote
culturing stage. For this reason only one unique location could be imaged for each sample since
the sample couldn’t be moved once placed in the culturing stage. However, unlike the static flow
conditions, the images could be taken at a much closer interval, in this case every 15 minutes
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essentially creating a video as the cells fill in the wound bed. In all cases, no matter how the
photos were taken, all photos were analyzed the same way.

Using the ImageJ software, freely downloaded from the NIH website, the wound bed gap
distance was measured and recorded in an excel spreadsheet. Before using the ImageJ software
the scale first had to be calibrated before measurements could be obtained. To calibrate the scale,
a photo of a 2 mm scale bar, shown below in Appendix I Photo 5, taken at the same
magnification of the cells in the experiment (10x) was used. Once the scale had been calibrated
the images were analyzed. For each image three unique distance measurements were obtained,
one on the far left, one in the center, and one on the far right. The wound boundary on each side
was identified as best as possible and this became the start and the finish of the distance
measurements. A depiction of how these three measurements were taken is shown below in
Appendix I Photo 9. After obtaining the distance measurements, they were all converted into a
percent representing the closure when compared to the original wound channel distance. By
converting these measurements to a percent it eliminates any bias caused by different initial
wound channel lengths which greatly reduces the expressed standard deviation.

MTT Assay of Cells After Imaging:
After the imaging sequence had been completed an MTT assay was run on a select
number of samples from each testing group. While an MTT assay is normally used to determine
the number of metabolically active cells in a culture dish, it can also be used to assess the degree
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of mitochondrial activity exhibited by the sample if the amount of cells remains constant from
sample to sample.

To conduct the MTT assay the reagent solutions were created according to the Vybrant
recommended protocol [37]. A 12 mM MTT stock solution was created by adding 1 mL of
sterile PBS to one 5 mg vial of MTT Component A (Invitrogen-Molecular Probes, Eugene,
Oregon). A second reagent solution is created by adding 10 mL of 0.01 M HCl to one tube
containing 1 g of SDS Component B (Invitrogen-Molecular Probes, Eugene, Oregon) contained
in the same kit as the MTT component.

Since the culture dished used in this experimentation differ in surface area from the ones
used in the Vybrant MTT assay protocol the amounts of each reagent used had to be scaled
accordingly. It was determined that a scaling factor of 9 should be used on all values discussed in
the Vybrant protocol. This means that to begin the MTT assay all media was removed from the
culture dishes and was replaced with 900 μL of fresh media. At this point 90 μL of the MTT
reagent solution to each culture dish and were placed in the incubator at 37oC for 4 hours. After
the incubation period was complete the samples were removed and 900 μL of the SDS reagent
solution was added to them and mixed thoroughly with a pipette. After mixing the samples were
placed back in the incubator at 37oC for another 4 hours. After this final incubation period the
samples were removed, mixed again, and tested for absorbance measurements at 570 nm using a
spectrometer. This is how the MTT assay was conducted for all samples in this investigation.
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Results:
Vesicle Binding by Native Media Proteins:
With this information generated from this experiment one can now estimate the sum of
the area under the lipid fluorescence curve and compare that to the sum of the area under the
protein bound lipid curves. Since the exact equation of the curve is unknown, a trapezoidal
approximation was conducted to get as close to the actual area as possible. The trapezoidal
approximation for each of the media samples can be found in Appendix II Chart 1 for the EGM2 media and Chart 2 for the M-106 media. A summarized chart of this data is shown below.
EGM-2

M-106

Percent Percent
Vesicle
Vesicle
Sample Bound
Free
1 59.03% 40.97%
2 57.63% 42.37%
3 54.60% 45.40%

Percent Percent
Vesicle
Vesicle
Sample Bound
Free
1 58.16% 41.84%
2 63.79% 36.21%
3 60.13% 39.87%

Avg
STDEV

Avg
STDEV

57.08%
2.26%

42.92%
2.26%

60.69%
2.85%

39.31%
2.85%

Chart 7: Averages and standard deviations for the ratio of lipid vesicles bound to media proteins
for each media type.

Looking at the results it is clear that in both media conditions a little over half of the
injected lipid vesicles are bound by the native proteins, meaning that for the desired 0.1 mg/mL
working concentration to be attained, 0.244 mg/mL must be injected into the EGM-2 culture
media and 0.254 mg/mL must be injected into the M-106 culture media. This number the
guidance for how much of the lipid vesicle mixture should be added to the media in future
experiments in order to achieve the correct working concentration.
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Flow Field Verification:
Analyzing the video in slow motion produced a flow velocity of v=2.97x10-4 m/s, a rate
consistent with the theoretical output of the continuous flow drug delivery device. Using the
equation:
Q=vbh
where v is the flow velocity and b and h are the dimensions of the culture dish, one can calculate
the flow rate of the system. This turns out to be Q=0.267 mL/min, again consistent with the
theoretical output of the drug delivery device. Using this flow rate one can plug it into the
equation for shear stress:
T=(6Qu)/(bh2)
where u is the viscosity of the culture media. Plugging all terms into this equation yields a shear
stress, which the cells experience, of 5.9x10-4 N/m2, which is well below the target shear stress of
0.3N/m2 meaning that these conditions won’t influence differentiation of the HUVEC cells. One
final bit of validation was to determine the Reynolds number with regards to the type of flow.
The equation used in this case is:
Re=ρvl/u
where ρ is the density of the media, v is the velocity, and u is the viscosity over the respective
length l. Substituting these values gives a Reynolds number of 1.612. A Reynolds number of less
than 2300 tends to indicate laminar flow. In this case laminar flow makes sense because the
media is flowing so slowly there is nothing to disturb the fluid layers and cause turbulent flow.
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Wound Closure Rate:
It is important to note that this system required many iterations in order to integrate all
the many functional components of the experimental system. For example, the media reservoir
required a specially designed heating system to keep the cells exposed to 37°C media. Other
challenges included modifications to the height adjustments to the flow inlet or outlet to prevent
loss of culture media, random software crashes due to the massive amounts of data
accumulated/experiments, and issues with microscope failure where the bulb burned out from
prolonged use.
Results from the cellular model of wound closure are expressed as a rate measurement of
the changes in area over time. In addition an MTT assay on a portion of the samples in each of
the testing groups was analyzed to measure cell proliferation and mitochondrial activity. In
addition to these quantitative measurements, the photo sets were carefully inspected in an
attempt to gage the mechanism of cellular wound closure. In this case the goal was to determine
if cell proliferation, migration, or a combination of both was the primary mode of closure. No
physical numbers were generated in closure mechanism analysis; instead it was more of a
subjective investigation to see if there was a difference. In analyzing the data, a significant
difference in values between the sets was determined if the p-value from the student’s t test was
less than 0.05. Before the student’s t test was conducted an f test first had to be conducted to
determine if the data sets had equal or unequal variance, which determines the type of t test to
run.
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Cellular Model of Wound Closure Data:
Looking at the data generated from the Image J measurements and averaging them
together generates the graphs shown in Figures 13-15 for the HUVEC cells and Figures 16-18
for the HDFA cells.

HUVEC Flow Vs. No Flow
Remaining Wound Percentage
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Figure 13: Comparison between HUVEC Flow and No Flow conditions. HUVEC Flow showed
significantly faster closure rates than HUVEC No Flow (p=0.00165).

To prove the first hypothesis whether low flow influences cellular wound closure rates,
the data was examined between the HUVEC Flow and No Flow conditions. It was shown that
HUVEC Flow had an average rate of closure of 0.0628 percent per minute whereas the HUVEC
No Flow had an average rate of closure of 0.0232. This resulted in a significant difference
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(p=0.00165) between Flow and No Flow conditions thus proving the initial hypothesis that low
flow rate can accelerate wound closure at least in the HUVEC cell culture model.

HUVEC Vitasol Vs. No Vitasol Under Flow
Conditions
Remaining Wound Percentage
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Figure 14: Comparison between HUVEC VitaSol and No VitaSol conditions when subjected to a
flow environment. There was no observed difference between the closure rates for the HUVEC
VitaSol and No VitaSol testing groups (p=0.3566).

To prove the secondary hypothesis whether VitaSol influences the wound closure rate,
the data was examined between the HUVEC VitaSol and No VitaSol conditions when subjected
to a flow environment. It was shown that HUVEC VitaSol had an average rate of closure of
0.0730 percent per minute whereas the HUVEC No VitaSol had an average rate of closure of
0.0628. This did not result in a significant difference (p=0.3566) between VitaSol and No
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VitaSol conditions thus suggesting that the secondary hypothesis, that adding VitaSol can
accelerate wound closure, may not be true.

HUVEC
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Figure 15: Comparison between all HUVEC testing groups. There was no observed difference
between any of the VitaSol testing groups (p=0.3566 and 0.4080 for Flow and No Flow
conditions respectively). There was a significant difference between the Flow and No Flow
testing groups (p=0.00165 and 0.00980 with and without VitaSol respectively).

The raw data used to generate these graphs can be found in Appendix II Chart 3 for the
HUVEC cells. Taking the closure measurements one can calculate the rate of closure between
each step. Doing so yields the data found in Appendix II Chart 5 for the HUVEC cells. The
summarized averages and standard deviations for each of the testing groups are shown in the
tables below.
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6
6
5

Average Rate
Percent/min
0.0232
0.0170
0.0628

Average
STDEV
0.0122
0.0105
0.0168

4

0.0730

0.0225

Number of Samples
Huvec Control
Huvec 0.1 mg/mL VitaSol
Huvec 90 Degree Flow
Huvec Flow 0.1mg/mL
VitaSol

Huvec Control
Huvec 0.1mg/mL VitaSol
Huvec 90 Degree Flow
Huvec Flow 0.1mg/mL
VitaSol

Huvec
Control
0.4080
0.0016

Huvec 0.1mg/mL
VitaSol
1.024E-06

Huvec 90 Degree
Flow
-

0.0012

0.0098

0.3566

Chart 8: Averages and standard deviations for HUVEC cell rate of closure as well as p-values
between testing groups.
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HDFa Flow Vs. No Flow
Remaining Wound Percentage
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Figure 16: Comparison between HDFa Flow and No Flow conditions. HDFa Flow showed
significantly faster closure rates than HDFa No Flow (p=0.01606).
To prove the first hypothesis whether low flow influences cellular wound closure rates,
the data was examined between the HDFa Flow and No Flow conditions. It was shown that
HDFa Flow had an average rate of closure of 0.0595 percent per minute whereas the HUVEC No
Flow had an average rate of closure of 0.0392. This resulted in a significant difference
(p=0.01606) between Flow and No Flow conditions thus conclusively proving the initial
hypothesis that low flow rate can accelerate wound closure in both the HUVEC and HDFa cell
culture models.
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HDFa Vitasol Vs. No Vitasol Under Flow
Conditions
Remaining Wound Percentage

100
90
80

y = -0.0639x + 100.89
R² = 0.9945

70
y = -0.0636x + 98.38
R² = 0.9913

60
50
40
0

100

200

300

400

500

600

700

800

900

1000

Time (minutes)
HDFa Vitasol

HDFa No Vitasol

Figure 17: Comparison between HDFa VitaSol and No VitaSol conditions when subjected to a
flow environment. There was no observed difference between the closure rates for the HDFa
VitaSol and No VitaSol testing groups (p=0.3314).

To prove the secondary hypothesis whether VitaSol influences the wound closure rate,
the data was examined between the HDFa VitaSol and No VitaSol conditions when subjected to
a flow environment. It was shown that HDFa VitaSol had an average rate of closure of 0.0661
percent per minute whereas the HDFa No VitaSol had an average rate of closure of 0.0595. This
did not result in a significant difference (p=0.3314) between VitaSol and No VitaSol conditions
further suggesting that the secondary hypothesis, that adding VitaSol can accelerate wound
closure, may not be true since this was the case in both HUVEC and HDFa culture models.
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Figure 18: Comparison between all HDFa testing groups. There was no observed difference
between any of the VitaSol testing groups (p=0.0794 and 0.3314 for Flow and No Flow
conditions respectively). There was a significant difference between the Flow and No Flow
testing groups (p=0.01606 and 0.00386 with and without VitaSol respectively).

The raw data used to generate these graphs can be found in Appendix II Chart 4 for the
HDFa cells. Taking the closure measurements one can calculate the rate of closure between each
step. Doing so yields the data found in Appendix II Chart 6 for the HDFa cells. The summarized
averages and standard deviations for each of the testing groups are shown in the tables below.
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5
6
5

Average Rate
Percent/min
0.0392
0.0156
0.0595

Average
STDEV
0.0118
0.0579
0.0210

5

0.0661

0.0244

Number of Samples
HDFa Control
HDFa 0.1mg/mL VitaSol
HDFa 90 Degree Flow
HDFa Flow 0.1mg/mL
VitaSol

HDFa Control
HDFa 0.1mg/mL VitaSol
HDFa 90 Degree Flow
HDFa Flow 0.1mg/mL
VitaSol

HDFa
Control
0.0794
0.0160

HDFa 0.1mg/mL
VitaSol
0.0035

HDFa 90 Degree
Flow
-

0.0058

0.0038

0.3314

Chart 9: Averages and standard deviations for HDFa cell rate of closure as well as p-values
between testing groups.

To check for statistical significance an f test first had to be run comparing each of the test
groups to one another. The f test determines if the variance between the groups is equal or
unequal and based on this result, the proper t test can be chosen. Running the appropriate t test
for each comparison yields the full statistical tables seen in Appendix 2 Tables 1 through 12.
Representative photos of each of the testing groups can be found in Appendix III.

MTT Mitochondrial Activity Assay:
As mentioned previously an MTT assay was attempted on select samples within each of
the testing groups in order to try to gauge the level of mitochondrial activity displayed between
each set. The results of this analysis are shown in the table below as well as a graphical
representation.
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Absorbance

MTT Assay Flow Vs. No Flow
0.0350
0.0340
0.0330
0.0320
0.0310
0.0300
0.0290
0.0280
0.0270
0.0260
0.0250

Huvec Control
Huvec 90 Degree Flow
HDFa Control
HDFa 90 Degree Flow

HUVEC

HDFa

Figure 19: MTT Assay comparison between Flow and No Flow conditions. No significant
difference was observed between Flow and No Flow for both HUVEC and HDFa culture models
(p=0.3265 and 0.1950 respectively).

To prove the tertiary hypothesis, whether low flow rates induce higher mitochondrial
activity, the data was examined between the HUVEC and HDFa Flow and No Flow conditions.
It was shown that HUVEC Flow had an average absorbance 0.0328 whereas the HUVEC No
Flow had an average absorbance of 0.0316. The HDFA Flow had an average absorbance 0.0325
whereas the HDFa No Flow had an average absorbance of 0.0311. This did not result in a
significant difference (p=0.3265 and 0.1950) in mitochondrial activity for either HUVEC of
HDFa cultures respectively, as it pertains to flow. This suggests that the tertiary hypothesis may
not be true since this was the case in both HUVEC and HDFa culture models.
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MTT Assay Vitasol Vs. No Vitasol
Under Flow Conditions
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Absorbance
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Huvec Flow 0.1mg/mL
Vitasol
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HDFa 90 Degree Flow

0.0270

HDFa Flow 0.1mg/mL
Vitasol

0.0250
HUVEC
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Figure 20: MTT Assay comparison between VitaSol and No VitaSol conditions. No significant
difference was observed between VitaSol and No VitaSol for both HUVEC and HDFa culture
models (p=0.5947 and 0.4156 respectively).

To prove the tertiary hypothesis, whether the addition of VitaSol induces higher
mitochondrial activity, the data was examined between the HUVEC and HDFa VitaSol and No
VitaSol conditions. It was shown that HUVEC VitaSol had an average absorbance 0.0326
whereas the HUVEC No VitaSol had an average absorbance of 0.0328. The HDFA VitaSol had
an average absorbance 0.0327 whereas the HDFa No VitaSol had an average absorbance of
0.0325. This did not result in a significant difference (p=0.5947 and 0.4156) in mitochondrial
activity for either HUVEC of HDFa cultures respectively, as it pertains to the addition of
VitaSol. This suggests that the tertiary hypothesis may not be true since this was the case in both
HUVEC and HDFa culture models.
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MTT Assay Results
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Figure 21: MTT Assay comparison between all testing groups for both HUVEC and HDFa
culture models. There was no observed difference between any of the testing groups on any level
for either the HUVEC of HDFa cultures.

To check for statistical significance an f test first had to be run comparing each of
the test groups to one another. The f test determines if the variance between the groups is equal
or unequal and based on this result, the proper t test can be chosen. Running the appropriate t test
for each comparison yields the full statistical tables seen in Appendix 2 Tables 13 through 24. A
summarized table of p-values is shown below.

Huvec Control
Huvec 0.1mg/mL VitaSol
Huvec 90 Degree Flow
Huvec Flow 0.1mg/mL
VitaSol

Huvec
Control
0.8212
0.3265

Huvec 0.1mg/mL
VitaSol
0.4973

Huvec 90 Degree
Flow
-

0.4038

0.5947

0.8414
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HDFa Control
HDFa 0.1mg/mL VitaSol
HDFa 90 Degree Flow
HDFa Flow 0.1mg/mL
VitaSol

HDFa
Control
0.6284
0.1950

HDFa 0.1mg/mL
VitaSol
0.4963

HDFa 90 Degree
Flow
-

0.1716

0.4156

0.8264

Chart 10: Summarized table of p-values for HUVEC and HDFa cellular MTT assay.
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Discussion:
Wound Closure Rate Data:
Looking at the data generated from the wound closure experiments a few things became
evident. First and foremost, it seems that the primary hypothesis was proven true. A continuous
flow of media over the cells does promote higher rates of growth and closure of the wound. This
is demonstrated by the p values less than 0.05 for all comparisons between the flow test groups
and the static test groups. Comparing the results of this experimentation to the known flow
effects on cells the data seems to coincide. While previous experiments used higher flow rates
than those used in this experimentation it appears that the same effects, accelerated growth rates,
are prevalent in both cases [22]. This means that when such a device is created, capable of
sustaining the flow of a drug, such as VitaSol, over a wound bed, it is expected that full closure
and healing of the wound would be expedited. By speeding up the wound healing process for
chronic ulcers or bedsores, which often take weeks of recuperation in a hospital, one could
expect to shorten these lengthy often uncomfortable stays, thus enhancing the quality of life for
many patients.

The secondary hypothesis in this investigation was far less definitive after all the results
had come in. The original intent was to demonstrate that by adding a drug to the circulating
media, this too will have a positive effect on the growth rate of the cells in culture. What was
seen from the data was that the VitaSol had no effect whatsoever on either of the cell culture
models. Comparing these results to the known effects of VitaSol on the cells they do not match
up. Previous experimentation saw profound effects on cellular growth rates when VitaSol was
added whereas in this experimentation no difference was observed. The reason for this lack of
40

effect can’t be definitively proven, but after a reexamination of the model used in this testing
method the likely reason is that the cells were grown under normal oxygen conditions. This is
further backed up by the fact that previous testing by other labs did in fact culture the cells under
hypoxic conditions whereas for this experimentation the cells were cultured under normoxia
conditions [27]. Under normal oxygen conditions the cells will produce adequate amounts of
ATP required for sustained growth. Since ATP is the functional aspect of the VitaSol treatment
given to the cells it would be treated as excess and disposed of by the cells. The result of this
being that the overall growth rates between the cells given the VitaSol infused media and those
given the standard media remains the same. Given the proper model a difference might be able to
be gleaned from the data. Clinically it is expected that VitaSol will accelerate healing rates since
this aspect has been definitively proven in bolus therapy just not yet so in continuously applied
therapy.

MTT Assay Data:
The data generated from the MTT assay was less conclusive. While the data itself is
reliable and accurate it doesn’t show any statistically significant differences in mitochondrial
activity between the testing groups. The simple explanation for this lack of significance is the
shortage of cells being tested with each run of the MTT assay. When creating the calibration
curve for the number of cells and the absorbance measurements they generate, one of the lowest
values of cells used is 50,000 while one of the upper values is 1,000,000 cells. The number of
cells able to be grown in micro incubation dishes used in the experimentation is roughly 100,000
cells at a max. The actual amount of cells contained in these dishes during experimentation was
roughly 75,000 based on cell counts using a hemocytometer. This 75,000 falls at the very low
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end of the calibration curve And could have contributed to the lack of differences noted here. It
is suggested that future experimentation in this area use greater than 75,000 used hereto
potentially detect significant differences between groups. It seems that the cells experiencing
flow tended to have higher absorbance measurements than the static conditions, 0.0328
compared to 0.0316 for the HUVEC cells and 0.0325 compared to 0.0311 for the HDFa cells,

Closure Mechanism Analysis:
This method of analysis, as mentioned earlier was purely subjective. Looking at the static
flow samples the primary wound closure mechanism was proliferation of the cells into the
simulated wound channel. While there was some migration of the cells, as they do naturally, the
migration that was seen was parallel to the wound channel and not into the wound. An example
of this is shown in Figure 7 below. With the low flow samples the primary wound closure
mechanism was a combination of proliferation and migration into the wound channel. It seems
that the flow directed the movement of the cells into the channel where they then began to
proliferate. An example of this is shown in Figure 8 below. In terms of wound healing in vivo,
migration of HUVEC cells into the wound could play an important role in their role in
neovascularization of the wound, which could speed the healing process. Migration of fibroblasts
into the wound is very important in laying down, extracellular matrix, increasing cellular
proliferation, and filling the wound are to prevent infection. In conclusion migration of the cells,
guided by the flow conditions expected to be produced from this device, will expedite the wound
healing process.

42

Figure 7: HUVEC cells in static conditions. Note high cell density on wound borders with some
lone migratory cells in the wound channel.

Figure 8: HUVEC cells in flow conditions. Note the medium cell density on the wound borders
with many lone migratory cells in the wound channel.
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Recommendations:
After spending time conducting these experiments it is evident that there is additional
experimentation which can be conducted to further enhance the conclusions drawn from this
experimental investigation. The first and foremost is modifying the model in order to show a
difference between the cells given the VitaSol supplemented media and those given the standard
media formulation. As mentioned briefly above in the discussion section, there was no
significant difference between the drug loaded media and the no drug loaded media when there
probably should have been. After much deliberation, this is thought to be the cause of the normal
oxygen conditions the cells were introduced to. In a normal oxygen environment the cells are
able to produce as much ATP as they need, which is the primary active molecule in the VitaSol.
Therefore any ATP delivered as a result of the VitaSol would be treated as excess by the cells
and would be discarded from the cells if it is even absorbed at all. It is therefore the
recommendation to repeat these experiments in a hypoxic environment where the cells are ATP
deprived, if this is the case then there should be a displayed difference between the VitaSol
samples and the regular media samples. Retesting the samples under hypoxic conditions would
probably also more accurately mimic in vivo conditions in a wound, which is often oxygen
deprived.

A second recommendation would be to retest the flow samples at different flow rates.
While this experimentation did show that flow has a significant effect in the rate of wound
closure it is unknown if the flow used in this investigation optimizes the rate of closure. For this
reason it would be desirable to attempt to maximize the rate of wound healing by testing at a
flow rate higher and lower than the one used in this experimentation and see if this makes a
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difference. It is fairly well documented that high flow rates accompanied with relatively higher
shear stresses enhances HUVEC cell growth rates especially when the cells are exposed to shear
stress prior to testing. There is very little documentation regarding what happens to the cells at
low flow rates with nearly negligible shear stresses, which is why further research into this area
is recommended.

A final recommendation would be to test whether flow directionality has a significant
impact on the rates of wound closure. For this experimentation a perpendicular flow to the
channel was chosen because that is what the literature precedent used, however, considering the
nature of a wound bed which is more radial it would be more realistic to test a variety of angles
of flow. It is theorized that a parallel angle of flow in comparison to the wound channel wouldn’t
direct the cells into the wound channel to the extent that the perpendicular flow did thus reducing
the rate of closure. However, since there is still the constant circulating of fresh media with the
removal of metabolytes would still lead to a significant difference in the rate of growth over the
static flow conditions.
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Conclusion:
Based on the results from the previously discussed experiments a few things can be
concluded. One such thing was that a flow rate, even a very low rate, such as the one used in this
experimentation, promotes cellular growth rates in both the HUVEC and the HDFa cell culture
models. This enhanced rate should translate to faster filling of the wound bed as well as the faster
revascularization of the wound bed. Another thing concluded from this round of experimentation
is that the VitaSol did not have any effect on the growth rate, although likely for the reasons
discussed above. In a similar fashion the MTT assay also could not display statistically
significant results because the number of cells used in the assay was too low to display a
difference in the metabolic rates. Overall, even with some aspects of this investigation being
inconclusive, the experimentation was still a success as it proved the primary hypothesis. Despite
the setbacks exhibited during this investigation, the results can still be used as a reliable predicate
comparison for future experimentation in this area.
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Appendices:
Appendix I: Experimental Setup Photos

Additional Running Buffer Reservoir

Running Buffer Layer

Sample Loading Point

Packed Gel Layer

Sample Collection Point

Photo 1: Gel Filtration Column Setup with Extra Running Buffer Reservoir Attached
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Flow Inlet
Heating Element

Gas Inlet

Heating Element

Cell Culture Dish

Flow Outlet

Photo 2: DH-40i Microincubation System with labeled flow inlets and outlets designed to supply
media to the cell culture and heating elements, powered by DC current, designed to maintain
37oC.
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DC Power Supply

Thermal Probe
Attached to Display

Heating Elements

Photo 3: Temperature Verification Using the DC Power Supply set to maintain 37oC.
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DC Power Supply
Incubation System

Peristaltic Pump

Media Reservoir

Microscope with Attached
Camera System Above

Photo 4: Complete Cell Culturing System with attached peristaltic pump facilitating the flow of
media, DC Power supply to maintain physiologic growing temperatures, and attached camera
system for data collection.

Photo 5: 2mm Scale Bar Imaged at 10x used to calibrate the ImageJ software.
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Tracked Particle Time 1

Photo 6: Image of Particle Tracking Time 1

Tracked Particle Time 2

Photo 7: Image of Particle Tracking Time 2
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Tracked Particle Time 3

Photo 8: Image of Particle Tracking Time 3

Arrows Represent
Measurements Taken in ImageJ

Photo 9: Depiction of how the distance measurements were taken from each photo.
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Appendix II: Additional Data and Statistics
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Figure 1: EGM-2 Media Sample 1 Fluorescence Curve
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Figure 2: EGM-2 Media Sample 2 Fluorescence Curve
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Figure 3: EGM-2 Media Sample 3 Fluorescence Curve
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Figure 4: M-106 Media Sample 1 Fluorescence Curve
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Figure 5: M-106 Media Sample 2 Fluorescence Curve
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Figure 6: M-106 Media Sample 3 Fluorescence Curve
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Protein Absorbance - EGM-2 Sample 1
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Figure 7: EGM-2 Media Sample 1 Protein Absorbance Curve
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Figure 8: EGM-2 Media Sample 2 Protein Absorbance Curve
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Figure 9: EGM-2 Media Sample 3 Protein Absorbance Curve
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Figure 10: M-106 Media Sample 1 Protein Absorbance Curve
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Figure 11: M-106 Media Sample 2 Protein Absorbance Curve
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Figure 12: M-106 Media Sample 3 Protein Absorbance Curve
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EGM-2 Sample 1
Area under curve

1
2
3
4
5
6
7
Total

Lipids
6.3875
19.261
16.743
5.236

47.6275

EGM-2 Sample 2
Area under curve

EGM-2 Sample 3
Area under curve

Lipid and
Lipid and
Lipid and
Proteins Proteins
Lipids
Proteins Proteins
Lipids
Proteins Proteins
5.748
1
1.52
7.607
1
4.244
4.2815
11.1135
2
7.271
13.621
2
16.6405
9.81
10.297
3
23.2995
14.997
3
19.323 10.6615
9.384
4
25.6845
15.411
4
9.0845
9.6415
13.3085
5
11.3415 17.5215
5
10.9395
12.378
6
15.2175
6
9.184
6.38
7
7.5585
7
4.7575
68.609 116.2365 Total
67.5965 91.9335
159.53 Total
49.292 59.2755 108.5675

Percent Vesicle Bound= 0.590253
Percent Vesicle Free= 0.409747

Percent Vesicle Bound= 0.576277
Percent Vesicle Free= 0.423723

Avg
STDEV

Bound
Free
0.570836 0.429164
0.022633 0.022633

Chart 1: Area Approximations under the EGM-2 Media Curve
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Percent Vesicle Bound= 0.545978
Percent Vesicle Free= 0.454022

M-106 Sample 1
Area under curve

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Total

M-106 Sample 2
Area under curve

M-106 Sample 3
Area under curve

Lipid and
Lipid and
Lipid and
Lipids
Proteins Proteins
Lipids
Proteins Proteins
Lipids
Proteins Proteins
8.8245
3.723
1
4.568
5.9105
1
4.8755
4.9335
18.716
5.0485
2
12.8565
8.8015
2
13.5895
7.78
14.6165
5.8655
3
20.7435
9.94
3
21.6365
9.4985
6.851
5.1365
4
18.0495
9.526
4
19.9465
9.165
4.103
4.792
5
9.838
9.9285
5
10.827
8.586
5.415
6
5.808
10.402
6
4.9615
8.481
3.7895
7
9.023
7
8.5905
4.639
8
9.068
8
8.2365
5.328
9
7.6955
9
8.441
5.64
10
6.9025
10
8.3545
5.5595
11
8.1015
11
6.544
5.1115
12
8.4275
12
6.588
4.528
13
7.596
13
7.3065
3.57
14
6.939
14
5.9375
2.9225
15
5.3315
15
4.1305
1.535
16
2.989
16
1.818
0.214
Total
71.8635 126.582 198.4455 Total
75.8365 114.391 190.2275
1.0125
53.111
73.83 126.941
Percent Vesicle Bound= 0.581609
Percent Vesicle Free= 0.418391

Percent Vesicle Bound= 0.637868
Percent Vesicle Free= 0.362132

Avg
STDEV

Bound
Free
0.606938 0.393062
0.028545 0.028545

Chart 2: Area Approximations under the M-106 Media Curve
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Percent Vesicle Bound= 0.601338
Percent Vesicle Free= 0.398662

Time Minutes
0
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720
1250
1580
2855
3130
4220
4490
5615
5895

Huvec
Control
100
83.26424961
80.26479179
63.42235514
50.60951082
33.27561782
21.03643073
0

Remaining Wound Percentage
Huvec
Huvec Flow
0.1mg/mL
Huvec Flow
0.1mg/mL
VitaSol
VitaSol
100
75.13798662
66.75377326
55.39735261
51.58012993
30.44741855
24.9938944
14.18209349
5.966394764

100
100
87.08283323 82.66307058
74.66724515 69.81484197
64.52112872 58.55846844
55.85032968

Chart 3: Data Used to Generate Wound Closure Curves for the HUVEC Cells

Time Minutes
0
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Control

Remaining Wound Percentage
HDFa
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HDFa Flow
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HDFa Flow
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VitaSol

100
100
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100
88.49115244 86.43940776
85.41688766 84.63543526
79.24206727 73.52470722
68.98591408 62.97892903
53.49474493 54.50450009
42.50004177
49.05855521 54.14554024
33.90527209 35.50132115
0
0

Chart 4: Data Used to Generate Wound Closure Curves for the HDFa Cells
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Growth Rate at Each Sample

Huvec Control

1
2
3
4
5
6
7
8

-0.013863736
-0.00795523
-0.013014089
-0.047633303
-0.016072551
-0.045746476
-0.018206536

Average
STDEV

-0.023213132
0.016352296

Huvec Flow

Huvec
Flow
0.1mg/mL
VitaSol

-0.019684724
-0.029870737
-0.009168305
-0.016363491
-0.015010376
-0.017033163
-0.01239481
-0.020031866

-0.071762038
-0.068975489
-0.056367313
-0.054288537

-0.096316
-0.071379
-0.051371
-0.073022

-0.017444684
0.006180406

-0.062848344
0.008799051

-0.073022
0.0183857

Huvec
0.1mg/mL
VitaSol

Chart 5: Closure Rate Measurements for the HUVEC Culture Model

Growth Rate at Each Sample

HDFa Control

HDFa
0.1mg/mL
VitaSol

1
2
3
4
5

-0.05224799
-0.037030271
-0.038179228
-0.029723942

0.014101792
-0.018881575
-0.029585663
-0.028141292

-0.070210305
-0.046564877
-0.058070382
-0.05500393
-0.068119618

Average
STDEV

-0.039295358
0.009412032

-0.015626684
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0.009728056

Chart 6: Closure Rate Measurements for the HDFa Culture Model
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HDFa Flow

HDFa
Flow
0.1mg/mL
VitaSol
-0.075337
-0.071748
-0.058588
-0.058754

-0.066107
0.0087104

Statistical Tables:
Wound Closure Rate Statistics:
F-Test Two-Sample for Variances
Huvec Control Vs. Huvec VitaSol
Variable 1 Variable 2
Mean
0.0232131 0.0174447
Variance
0.0002674
3.82E-05
Observations
7
8
df
6
7
F
7.000409
P(F<=f) one-tail
0.0107815
F Critical one-tail
3.8659689
P<0.05 so assume unequal variance
t-Test: Two-Sample Assuming Unequal Variances
Huvec Control Vs. Huvec VitaSol
Variable 1 Variable 2
Mean
0.0232131 0.0174447
Variance
0.0002674
3.82E-05
Observations
7
8
Hypothesized Mean Difference
0
df
7
t Stat
0.8799427
P(T<=t) one-tail
0.2040411
t Critical one-tail
1.8945786
P(T<=t) two-tail
0.4080822
t Critical two-tail
2.3646243
P>0.05 so there is no significant difference between
groups

Table 1: Statistical Table Huvec Control Vs. Huvec VitaSol
F-Test Two-Sample for Variances
Huvec Control Vs. Huvec Flow
Mean
Variance
Observations

Variable 1
-0.0232131
0.0002674
7
67

Variable 2
-0.0628483
7.742E-05
4

df
F
P(F<=f) one-tail
F Critical one-tail
P>0.05 so assume equal variance

6
3.4537096
0.1682448
8.9406451

3

t-Test: Two-Sample Assuming Equal Variances
Huvec Control Vs. Huvec Flow
Variable 1
Variable 2
Mean
-0.0232131 -0.0628483
Variance
0.0002674
7.742E-05
Observations
7
4
Pooled Variance
0.0002041
Hypothesized Mean Difference
0
df
9
t Stat
4.4266102
P(T<=t) one-tail
0.0008276
t Critical one-tail
1.8331129
P(T<=t) two-tail
0.0016553
t Critical two-tail
2.2621572
P<0.05 so there is a statistically significant difference between
groups

Table 2: Statistical Table Huvec Control Vs. Huvec Flow
F-Test Two-Sample for Variances
Huvec VitaSol Vs. Huvec Flow
Variable 1
Mean
Variance
Observations
df
F
P(F<=f) one-tail
F Critical one-tail
P>0.05 so assume equal variance

Variable 2

0.017444684
3.81974E-05
8
7
0.49335826
0.198800536
0.230052631

-0.062848344
7.74233E-05
4
3

t-Test: Two-Sample Assuming Equal Variances
Huvec VitaSol Vs. Huvec Flow
Variable 1
Mean
-

Variable 2
-0.062848344
68

0.017444684
Variance
3.81974E-05
7.74233E-05
Observations
8
4
Pooled Variance
4.99652E-05
Hypothesized Mean Difference
0
df
10
t Stat
10.48917868
P(T<=t) one-tail
5.12156E-07
t Critical one-tail
1.812461102
P(T<=t) two-tail
1.02431E-06
t Critical two-tail
2.228138842
P<0.05 so there is a statistically significant difference between
groups

Table 3: Statistical Table Huvec VitaSol Vs. Huvec Flow
F-Test Two-Sample for Variances
Huvec Control Vs. Huvec Flow VitaSol
Mean
Variance
Observations
df
F
P(F<=f) one-tail
F Critical one-tail
P>0.05 so assume equal variance

Variable 1
-0.02321
0.000267
7
6
0.791034
0.367816
0.210214

t-Test: Two-Sample Assuming Equal Variances
Huvec Control Vs. Huvec Flow VitaSol
Variable 1
Mean
-0.02321
Variance
0.000267
Observations
7
Pooled Variance
0.000291
Hypothesized Mean Difference
0
df
9
t Stat
4.658913
P(T<=t) one-tail
0.000594
t Critical one-tail
1.833113
P(T<=t) two-tail
0.001187
t Critical two-tail
2.262157
69

Variable 2
-0.07302
0.000338
4
3

Variable 2
-0.07302
0.000338
4

P<0.05 so there is a statistically significant difference between
groups

Table 4: Statistical Table Huvec Control Vs. Huvec Flow VitaSol
F-Test Two-Sample for Variances
Huvec VitaSol Vs. Huvec Flow VitaSol
Mean
Variance
Observations
df
F
P(F<=f) one-tail
F Critical one-tail
P<0.05 so assume unequal variance

Variable 1
-0.01744
3.82E-05
8
7
0.112998
0.008839
0.230053

Variable 2
-0.07302
0.000338
4
3

t-Test: Two-Sample Assuming Unequal Variances
Huvec VitaSol Vs. Huvec Flow VitaSol
Variable 1 Variable 2
Mean
-0.01744
-0.07302
Variance
3.82E-05
0.000338
Observations
8
4
Hypothesized Mean Difference
0
df
3
t Stat
5.881816
P(T<=t) one-tail
0.004903
t Critical one-tail
2.353363
P(T<=t) two-tail
0.009806
t Critical two-tail
3.182446
P<0.05 so there is a statistically significant difference between
groups

Table 5: Statistical Table Huvec VitaSol Vs. Huvec Flow VitaSol
F-Test Two-Sample for Variances
Huvec Flow Vs. Huvec Flow VitaSol

Mean
Variance
Observations
df
F

Variable Variable
1
2
-0.06285 -0.07302
7.74E-05 0.000338
4
4
3
3
0.229039
70

P(F<=f) one-tail
F Critical one-tail
P>0.05 so assume equal variance

0.128663
0.107798

t-Test: Two-Sample Assuming Equal Variances
Huvec Flow Vs. Huvec Flow VitaSol
Variable Variable
1
2
Mean
-0.06285 -0.07302
Variance
7.74E-05 0.000338
Observations
4
4
Pooled Variance
0.000208
Hypothesized Mean Difference
0
df
6
t Stat
0.998255
P(T<=t) one-tail
0.178349
t Critical one-tail
1.94318
P(T<=t) two-tail
0.356697
t Critical two-tail
2.446912
P>0.05 so there is no significant difference between
groups

Table 6: Statistical Table Huvec Flow Vs. Huvec Flow VitaSol
F-Test Two-Sample for Variances
HDFa Control Vs. HDFa VitaSol
Variable 1
Mean
Variance
Observations
df
F
P(F<=f) one-tail
F Critical one-tail
P>0.05 so assume equal variance

-0.039295358
8.85864E-05
4
3
0.213316284
0.118324374
0.107797789

t-Test: Two-Sample Assuming Equal Variances
HDFa Control Vs. HDFa VitaSol
Variable 1
Mean
Variance

-0.039295358
8.85864E-05
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Variable 2
0.015626684
0.000415282
4
3

Variable 2
0.015626684
0.000415282

Observations
4
Pooled Variance
0.000251934
Hypothesized Mean Difference
0
df
6
t Stat
-2.1088491
P(T<=t) one-tail
0.039749589
t Critical one-tail
1.943180274
P(T<=t) two-tail
0.079499177
t Critical two-tail
2.446911846
P>0.05 so there is no statistically significant difference between
groups

Table 7: Statistical Table HDFa Control Vs. HDFa VitaSol
F-Test Two-Sample for Variances
HDFa Control Vs. HDFa Flow
Mean
Variance
Observations
df
F
P(F<=f) one-tail
F Critical one-tail
P>0.05 so assume equal variance

Variable 1
Variable 2
-0.0392954 -0.0595938
8.859E-05 9.464E-05
4
5
3
4
0.9360837
0.4983734
0.109683

t-Test: Two-Sample Assuming Equal Variances
HDFa Control Vs. HDFa Flow
Variable 1
Variable 2
Mean
-0.0392954 -0.0595938
Variance
8.859E-05 9.464E-05
Observations
4
5
Pooled Variance
9.204E-05
Hypothesized Mean Difference
0
df
7
t Stat
3.154003
P(T<=t) one-tail
0.008031
t Critical one-tail
1.8945786
P(T<=t) two-tail
0.0160621
t Critical two-tail
2.3646243
P<0.05 so there is a statistically significant difference between
groups

Table 8: Statistical Table HDFa Control Vs. HDFa Flow
72

4

F-Test Two-Sample for Variances
HDFa VitaSol Vs. HDFa Flow
Variable 1
Mean
Variance
Observations
df
F
P(F<=f) one-tail
F Critical one-tail
P>0.05 so assume equal variance

Variable 2

0.015626684
0.000415282
4
3
4.38824309
0.093531467
6.591382117

-0.059593823
9.46351E-05
5
4

t-Test: Two-Sample Assuming Equal Variances
HDFa VitaSol Vs. HDFa Flow
Variable 1

Variable 2

Mean
0.015626684
-0.059593823
Variance
0.000415282
9.46351E-05
Observations
4
5
Pooled Variance
0.000232055
Hypothesized Mean Difference
0
df
7
t Stat
4.302554925
P(T<=t) one-tail
0.001777716
t Critical one-tail
1.894578604
P(T<=t) two-tail
0.003555432
t Critical two-tail
2.364624251
P<0.05 so there is a statistically significant difference between
groups

Table 9: Statistical Table HDFa VitaSol Vs. HDFa Flow
F-Test Two-Sample for Variances
HDFa Control Vs. HDFa Flow VitaSol
Mean
Variance
Observations
df
F
P(F<=f) one-tail

Variable 1 Variable 2
-0.0393
-0.06611
8.86E-05
7.59E-05
4
4
3
3
1.167591
0.450828
73

F Critical one-tail
P>0.05 so assume equal variance

9.276628

t-Test: Two-Sample Assuming Equal Variances
HDFa Control Vs. HDFa Flow VitaSol
Variable 1 Variable 2
Mean
-0.0393
-0.06611
Variance
8.86E-05
7.59E-05
Observations
4
4
Pooled Variance
8.22E-05
Hypothesized Mean Difference
0
df
6
t Stat
4.181407
P(T<=t) one-tail
0.002902
t Critical one-tail
1.94318
P(T<=t) two-tail
0.005804
t Critical two-tail
2.446912
P<0.05 so there is a statistically significant difference between
groups

Table 10: Statistical Table HDFa Control Vs. HDFa Flow VitaSol
F-Test Two-Sample for Variances
HDFa VitaSol Vs. HDFa Flow VitaSol
Mean
Variance
Observations
df
F
P(F<=f) one-tail
F Critical one-tail
P>0.05 so assume equal variance

Variable 1 Variable 2
-0.01563
-0.06611
0.000415
7.59E-05
4
4
3
3
5.473522
0.098154
9.276628

t-Test: Two-Sample Assuming Equal Variances
HDFa VitaSol Vs. HDFa Flow VitaSol
Variable 1 Variable 2
Mean
-0.01563
-0.06611
Variance
0.000415
7.59E-05
Observations
4
4
Pooled Variance
0.000246
Hypothesized Mean Difference
0
74

df
6
t Stat
4.555557
P(T<=t) one-tail
0.001935
t Critical one-tail
1.94318
P(T<=t) two-tail
0.003869
t Critical two-tail
2.446912
P<0.05 so there is a statistically significant difference between
groups

Table 11: Statistical Table HDFa VitaSol Vs. HDFa FlowVitaSol
F-Test Two-Sample for Variances
HDFa Flow Vs. HDFa Flow VitaSol
Mean
Variance
Observations
df
F
P(F<=f) one-tail
F Critical one-tail
P>0.05 so assume equal variance

Variable 1
-0.05959
9.46E-05
5
4
1.247315
0.44565
9.117182

Variable 2
-0.06611
7.59E-05
4
3

t-Test: Two-Sample Assuming Equal Variances
HDFa Flow Vs. HDFa Flow VitaSol
Variable 1 Variable 2
Mean
-0.05959
-0.06611
Variance
9.46E-05
7.59E-05
Observations
5
4
Pooled Variance
8.66E-05
Hypothesized Mean Difference
0
df
7
t Stat
1.043342
P(T<=t) one-tail
0.165738
t Critical one-tail
1.894579
P(T<=t) two-tail
0.331477
t Critical two-tail
2.364624
P>0.05 so there is no statistically significant difference between
groups

Table 12: Statistical Table HDFa Flow Vs. HDFa FlowVitaSol
MTT Assay Statistics:
F-Test Two-Sample for Variances
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Huvec Control Vs. Huvec VitaSol

Mean
Variance
Observations
df
F
P(F<=f) one-tail
F Critical one-tail
P>0.05 so assume equal variance

Variable 1
0.0316
0.00000193
3
2
0.712177122
0.415948276
0.052631579

Variable
2
0.0319
3E-06
3
2

t-Test: Two-Sample Assuming Equal Variances
Huvec Control Vs. Huvec VitaSol
Variable
Variable 1
2
Mean
0.0316
0.0319
Variance
0.00000193
3E-06
Observations
3
3
Pooled Variance
0.00000232
Hypothesized Mean Difference
0
df
4
t Stat
-0.24122532
P(T<=t) one-tail
0.410620638
t Critical one-tail
2.131846782
P(T<=t) two-tail
0.821241275
t Critical two-tail
2.776445105
P>0.05 so there is no significant difference between groups

Table 13: Statistical Table Huvec Control Vs. Huvec VitaSol
F-Test Two-Sample for Variances
Huvec Control Vs. Huvec Flow
Mean
Variance
Observations
df
F
P(F<=f) one-tail
F Critical one-tail
P>0.05 so assume equal

Variable 1
Variable 2
0.0316 0.032766667
0.00000193 1.34333E-06
3
3
2
2
1.436724566
0.410386965
19
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variance
t-Test: Two-Sample Assuming Equal Variances
Huvec Control Vs. Huvec Flow
Variable 1
Variable 2
Mean
0.0316 0.032766667
Variance
0.00000193 1.34333E-06
Observations
3
3
Pooled Variance
1.63667E-06
Hypothesized Mean
Difference
0
df
4
t Stat
1.116894881
P(T<=t) one-tail
0.163298694
t Critical one-tail
2.131846782
P(T<=t) two-tail
0.326597388
t Critical two-tail
2.776445105
P>0.05 so there is no significant difference between groups

Table 14: Statistical Table Huvec Control Vs. Huvec Flow
F-Test Two-Sample for Variances
Huvec Control Vs. Huvec Flow VitaSol
Variable Variable
1
2
Mean
0.0316 0.032567
Variance
1.93E-06 1.29E-06
Observations
3
3
df
2
2
F
1.492268
P(F<=f) one-tail
0.401241
F Critical one-tail
19
P>0.05 so assume equal variance
t-Test: Two-Sample Assuming Equal Variances
Huvec Control Vs. Huvec Flow VitaSol
Variable Variable
1
2
Mean
0.0316 0.032567
Variance
1.93E-06 1.29E-06
Observations
3
3
Pooled Variance
1.61E-06
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Hypothesized Mean Difference
0
df
4
t Stat
-0.93258
P(T<=t) one-tail
0.201916
t Critical one-tail
2.131847
P(T<=t) two-tail
0.403831
t Critical two-tail
2.776445
P>0.05 so there is no significant difference between
groups

Table 15: Statistical Table Huvec Control Vs. Huvec Flow VitaSol
F-Test Two-Sample for Variances
Huvec VitaSol Vs. Huvec Flow

Mean
Variance
Observations
df
F
P(F<=f) one-tail
F Critical one-tail
P>0.05 so assume equal variance

Variable Variable
1
2
0.0319 0.032767
2.71E-06 1.34E-06
3
3
2
2
2.01737
0.331414
19

t-Test: Two-Sample Assuming Equal Variances
Huvec VitaSol Vs. Huvec Flow
Variable Variable
1
2
Mean
0.0319 0.032767
Variance
2.71E-06 1.34E-06
Observations
3
3
Pooled Variance
2.03E-06
Hypothesized Mean Difference
0
df
4
t Stat
-0.7456
P(T<=t) one-tail
0.248669
t Critical one-tail
2.131847
P(T<=t) two-tail
0.497338
t Critical two-tail
2.776445
P>0.05 so there is no significant difference between
groups

Table 16: Statistical Table Huvec VitaSol Vs. Huvec Flow
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F-Test Two-Sample for Variances
Huvec VitaSol Vs. Huvec Flow VitaSol

Mean
Variance
Observations
df
F
P(F<=f) one-tail
F Critical one-tail
P>0.05 so assume equal variance

Variable Variable
1
2
0.0319 0.032567
2.71E-06 1.29E-06
3
3
2
2
2.095361
0.323064
19

t-Test: Two-Sample Assuming Equal Variances
Huvec VitaSol Vs. Huvec Flow VitaSol
Variable Variable
1
2
Mean
0.0319 0.032567
Variance
2.71E-06 1.29E-06
Observations
3
3
Pooled Variance
2E-06
Hypothesized Mean Difference
0
df
4
t Stat
-0.57711
P(T<=t) one-tail
0.297395
t Critical one-tail
2.131847
P(T<=t) two-tail
0.59479
t Critical two-tail
2.776445
P>0.05 so there is no significant difference between
groups

Table 17: Statistical Table Huvec VitaSol Vs. Huvec Flow VitaSol
F-Test Two-Sample for Variances
Huvec Flow Vs. Huvec Flow VitaSol

Mean
Variance
Observations
df
F
P(F<=f) one-tail

Variable Variable
1
2
0.032767 0.032567
1.34E-06 1.29E-06
3
3
2
2
1.03866
0.490518
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F Critical one-tail
P>0.05 so assume equal variance

19

t-Test: Two-Sample Assuming Equal Variances
Huvec Flow Vs. Huvec Flow VitaSol
Variable Variable
1
2
Mean
0.032767 0.032567
Variance
1.34E-06 1.29E-06
Observations
3
3
Pooled Variance
1.32E-06
Hypothesized Mean Difference
0
df
4
t Stat
0.213335
P(T<=t) one-tail
0.420749
t Critical one-tail
2.131847
P(T<=t) two-tail
0.841498
t Critical two-tail
2.776445
P>0.05 so there is no significant difference between
groups

Table 18: Statistical Table Huvec Flow Vs. Huvec Flow VitaSol
F-Test Two-Sample for Variances
HDFa Control Vs. HDFa VitaSol

Mean
Variance
Observations
df
F
P(F<=f) one-tail
F Critical one-tail
P>0.05 so assume equal variance

Variable 1
0.031133333
9.43333E-07
3
2
0.43404908
0.302673797
0.052631579

Variable
2
0.0317
2E-06
3
2

t-Test: Two-Sample Assuming Equal Variances
HDFa Control Vs. HDFa VitaSol

Mean
Variance
Observations

Variable
Variable 1
2
0.031133333
0.0317
9.43333E-07
2E-06
3
3
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Pooled Variance
Hypothesized Mean Difference
df

1.55833E-06
0
4
t Stat
0.523255952
P(T<=t) one-tail
0.314222195
t Critical one-tail
2.131846782
P(T<=t) two-tail
0.628444391
t Critical two-tail
2.776445105
P>0.05 so there is no significant difference between groups

Table 19: Statistical Table HDFa Control Vs. HDFa VitaSol
F-Test Two-Sample for Variances
HDFa Control Vs. HDFa Flow
Mean
Variance
Observations
df
F
P(F<=f) one-tail
F Critical one-tail
P>0.05 so assume equal
variance

Variable 1
Variable 2
0.031133333 0.032466667
9.43333E-07 1.26333E-06
3
3
2
2
0.746701847
0.427492447
0.052631579

t-Test: Two-Sample Assuming Equal Variances
HDFa Control Vs. HDFa Flow
Variable 1
Variable 2
Mean
0.031133333 0.032466667
Variance
9.43333E-07 1.26333E-06
Observations
3
3
Pooled Variance
1.10333E-06
Hypothesized Mean
Difference
0
df
4
t Stat
1.554644149
P(T<=t) one-tail
0.09750143
t Critical one-tail
2.131846782
P(T<=t) two-tail
0.195002861
t Critical two-tail
2.776445105
P>0.05 so there is no significant difference between groups
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Table 20: Statistical Table HDFa Control Vs. HDFa Flow
F-Test Two-Sample for Variances
HDFa Control Vs. HDFa Flow VitaSol

Mean
Variance
Observations
df
F
P(F<=f) one-tail
F Critical one-tail
P>0.05 so assume equal variance

Variable
1
0.031133
9.43E-07
3
2
0.54845
0.354193
0.052632

Variable
2
0.0327
1.72E-06
3
2

t-Test: Two-Sample Assuming Equal Variances
HDFa Control Vs. HDFa Flow VitaSol
Variable Variable
1
2
Mean
0.031133
0.0327
Variance
9.43E-07 1.72E-06
Observations
3
3
Pooled Variance
1.33E-06
Hypothesized Mean Difference
0
df
4
t Stat
-1.66274
P(T<=t) one-tail
0.085849
t Critical one-tail
2.131847
P(T<=t) two-tail
0.171699
t Critical two-tail
2.776445
P>0.05 so there is no significant difference between
groups

Table 21: Statistical Table HDFa Control Vs. HDFa Flow VitaSol
F-Test Two-Sample for Variances
HDFa VitaSol Vs. HDFa Flow

Mean
Variance
Observations
df

Variable Variable
1
2
0.031667 0.032467
2.17E-06 1.26E-06
3
3
2
2
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F
P(F<=f) one-tail
F Critical one-tail
P>0.05 so assume equal variance

1.720317
0.367604
19

t-Test: Two-Sample Assuming Equal Variances
HDFa VitaSol Vs. HDFa Flow
Variable Variable
1
2
Mean
0.031667 0.032467
Variance
2.17E-06 1.26E-06
Observations
3
3
Pooled Variance
1.72E-06
Hypothesized Mean Difference
0
df
4
t Stat
-0.74745
P(T<=t) one-tail
0.248169
t Critical one-tail
2.131847
P(T<=t) two-tail
0.496337
t Critical two-tail
2.776445
P>0.05 so there is no significant difference between
groups

Table 22: Statistical Table HDFa VitaSol Vs. HDFa Flow
F-Test Two-Sample for Variances
HDFa VitaSol Vs. HDFa Flow VitaSol

Mean
Variance
Observations
df
F
P(F<=f) one-tail
F Critical one-tail
P>0.05 so assume equal variance

Variable
1
0.031667
2.17E-06
3
2
1.263566
0.441781
19

t-Test: Two-Sample Assuming Equal Variances
HDFa VitaSol Vs. HDFa Flow VitaSol
Variable
1
Mean
0.031667

Variable
2
0.0327
1.72E-06
3
2

Variable
2
0.0327
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Variance
2.17E-06 1.72E-06
Observations
3
3
Pooled Variance
1.95E-06
Hypothesized Mean Difference
0
df
4
t Stat
-0.90707
P(T<=t) one-tail
0.207837
t Critical one-tail
2.131847
P(T<=t) two-tail
0.415673
t Critical two-tail
2.776445
P>0.05 so there is no significant difference between
groups

Table 23: Statistical Table HDFa VitaSol Vs. HDFa Flow VitaSol
F-Test Two-Sample for Variances
HDFa Flow Vs. HDFa Flow VitaSol

Mean
Variance
Observations
df
F
P(F<=f) one-tail
F Critical one-tail
P>0.05 so assume equal variance

Variable
1
0.032467
1.26E-06
3
2
0.734496
0.423464
0.052632

t-Test: Two-Sample Assuming Equal Variances
HDFa Flow Vs. HDFa Flow VitaSol
Variable
1
Mean
0.032467
Variance
1.26E-06
Observations
3
Pooled Variance
1.49E-06
Hypothesized Mean Difference
0
df
4
t Stat
-0.23398
P(T<=t) one-tail
0.413243
t Critical one-tail
2.131847
P(T<=t) two-tail
0.826485
t Critical two-tail
2.776445

Variable
2
0.0327
1.72E-06
3
2

Variable
2
0.0327
1.72E-06
3
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P>0.05 so there is no significant difference between
groups

Table 24: Statistical Table HDFa Flow Vs. HDFa Flow VitaSol
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Appendix III: Representative Photos From Each Testing Group
HUVEC Control Initial:

HUVEC Control Intermediate:
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HUVEC Control Final:

HUVEC VitaSol Initial:
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HUVEC VitaSol Intermediate:

HUVEC VitaSol Final:
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HUVEC Flow Initial:

HUVEC Flow Intermediate:
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HUVEC Flow Final:

HUVEC Flow VitaSol Initial:
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HUVEC Flow VitaSol Intermediate:

HUVEC Flow VitaSol Final:
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HDFa Control Initial:

HDFa Control Intermediate:
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HDFa Control Final:

HDFa VitaSol Initial:
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HDFa VitaSol Intermediate:

HDFa VitaSol Final:
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HDFa Flow Initial:

HDFa Flow Intermediate:
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HDFa Flow Final:

HDFa Flow VitaSol Initial:
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HDFa Flow VitaSol Intermediate:

HDFa Flow VitaSol Final:
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